**Is there a role for physical activity when treating cancer patients with immune checkpoint inhibitors? Protocol for a Scoping Review**

Miaoqi Chen1†, Ridesh Raj1†, Louis Fox1, Charlotte Moss1, Gincy George1, Sophia Karagiannis2,3, Deborah Enting4, Magdalene Joseph5, Nicola Peat6, Beth Russell1‡,Mieke Van Hemelrijck1‡

†Both first authors contributed equally

‡Both senior authors contributed equally

Affiliations:

1. Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom,
2. St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, King’s College London, London, United Kingdom;
3. Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, London, United Kingdom;
4. Guy’s and St Thomas’ NHS Foundation Trust (GSTT), Medical Oncology, London, United Kingdom;
5. Immunobiology, School of Immunology & Microbial Sciences, King’s College London, London, UK
6. Guy’s and St Thomas’ NHS Foundation Trust (GSTT), Physiotherapy Department, London, United Kingdom;

Email addresses: [chen.miaoqi@kcl.ac.uk](mailto:chen.miaoqi@kcl.ac.uk); [ridesh.raj@kcl.ac.uk](mailto:ridesh.raj@kcl.ac.uk); [louis.fox@kcl.ac.uk](mailto:louis.fox@kcl.ac.uk); [charlotte.moss@kcl.ac.uk](mailto:charlotte.moss@kcl.ac.uk); [Gincy.e.george@kcl.ac.uk](mailto:Gincy.e.george@kcl.ac.uk); [Sophia.karagiannis@kcl.ac.uk](mailto:Sophia.karagiannis@kcl.ac.uk); [Deborah.enting@kcl.ac.uk](mailto:Deborah.enting@kcl.ac.uk); [Magdalene.joseph@kcl.ac.uk](mailto:Magdalene.joseph@kcl.ac.uk); [nicola.peat@gstt.nhs.uk](mailto:nicola.peat@gstt.nhs.uk); [beth.russell@kcl.ac.uk](mailto:beth.russell@kcl.ac.uk); [mieke.vanhemelrijck@kcl.ac.uk](mailto:mieke.vanhemelrijck@kcl.ac.uk)

Corresponding author: Beth Russell

TOUR – KCL

Guy’s Hospital, 3rd Floor Bermondsey Wing, London SE1 9RT, UK

[beth.russell@kcl.ac.uk](mailto:beth.russell@kcl.ac.uk)

Keywords: physical activity, immune checkpoint inhibitors, cancer, quality of life

Funding: None to be declared.

**Abstract**

**Introduction**

For cancer patients, immune checkpoint inhibitors (ICIs) produce superior long-term responses compared to alternative treatments, albeit at the cost of manifesting adverse immune-related events. There are many hypotheses of the impacts of physical activities in immunotherapy, but little is known about the oncological outcomes and the underlying mechanisms. This scoping review aims to identify possible physical activity interventions, their efficacy and feasibility, and the potential underlying biological mechanisms responsible for their effects.

**Method and analysis**

The Levac methodology framework was used along with guidance from the Joanna Briggs Institute (JBI) Manual for Evidence Synthesis to inform development of this protocol. Abstracts and titles followed by full-text screening will be performed by two independent reviewers for inclusion. All studies describing the impact of physical activities and exercise interventions on cancer ICIs, with particular focus upon oncological outcomes, quality of life or underling biological mechanisms, will be included. After extracting qualitative and quantitative data, they will be evaluated and summarised respectively. Subsequently, a further consultation step with other scientists and healthcare professionals will be performed.

**Ethics and dissemination**

The research findings will be published through an open-access peer-reviewed journal. The results of this scoping review will be used to inform further studies on physical impacts on immunotherapy. All data included will be from open resources therefore no ethical clearances are required.

**Strengths and limitations of this study**

* Use of multiple databases to source literature
* Inclusion of consultation phase to include the viewpoint of healthcare professionals and scientists
* Quantitative analysis only possible if sufficient data is available

**Introduction**

As a leading cause of death in the U.K., cancer accounts for nearly a quarter of the total deaths between 2015-2017: around 367,000 new cancer cases occur in the UK every year, and almost 1,000 cases every day [1]. It is well established that engagement with physical activity (PA) (as defined by the World Health Organisation (WHO) as any bodily movement produced by skeletal muscles that requires energy expenditure [2]), is beneficial to patients diagnosed with cancer [3]. Suggested benefits of PA include improvements to cancer-specific quality of life, improvements to cancer-specific fatigue, and amelioration of certain treatment side effects such as pain, weakness and anxiety. However, a new line of investigation has emerged aiming to address whether the benefit of PA for cancer patients extends beyond symptom control [4–6]. For example, pre-clinical mouse melanoma models have shown that PA has an additive effect in controlling tumour progression in conjunction with programmed death-1 receptor (PD-1) blocking antibodies [7,8], without a pharmacological side effect profile.

With the recent advances in immunotherapy for cancer (i.e. the development of various immune checkpoint inhibitors), it is also of interest to note that preclinical studies have shown that PA may increase the number of dendritic cells [4]. Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and PD-1 and its ligand PD-L1 has become standard of care for an increasing number of cancer types, but come with a range of infusion reactions and both general and immune-related adverse events [5]. Despite immune checkpoint inhibitors (ICIs) being increasingly used to treat a variety of cancers, comparatively little is known about how to balance their response and adverse events. We hypothesise here than PA could be instrumental in this this balance. Since ICIs can achieve long-term responses superior to those seen with most other treatments, but only works in subsets of patients, treatments combined with alternative strategies that enhance responses are an important area of research.

**Methods**

**Study rationale**

PA is likely to have benefits in combination with cancer treatment with limited side effects and should therefore be explored further [3]. Thus, since ICIs are leading the way in the treatment of various cancers, the current scoping review specifically focuses on identifying what is already known about PA interventions in this immunotherapy setting [9,10] and where the current gaps are to advance current research.

**Study objectives**

In this scoping review, we aim to investigate the current evidence and gaps in our understanding of the effects of PA on ICIs for cancer, with a specific focus on: (1) oncological outcomes; (2) quality of life (QoL); and (3) potential underlying biological mechanisms.  **Protocol design**

The Joanna Briggs Institute (JBI) Manual for Evidence Synthesis was used as reference during the development of this protocol [11]. The overall protocol framework also closely resembles the methodological guidelines developed by Levac *et al* [12]. The protocol is also registered on <https://osf.io/>.

***Stage 1: Identifying the research question***

Following consultation with the clinical research team, the proposed research questions are defined as:

1. Is there any evidence that suggests that physical activity has a demonstrable effect upon improving the oncological outcomes of cancer patients receiving ICIs?
2. Is there any evidence that suggests that physical activity (including which type, timing and dosage of physical activity) has a demonstrable effect upon improving the quality of life of cancer patients receiving ICIs?
3. What are the biological mechanisms, if any, that could be responsible for the effects exerted by physical activity on improving the oncological outcomes and quality of life of cancer patients receiving ICIs?

***Stage 2: Identifying relevant studies – Search strategy***

The following electronic databases will be searched from inception until the date on which the searches will be performed: MEDLINE, Embase and PsycInfo. Search terms have been determined through researcher input and researching the current available literature to help guide the selection of terms – ensuring they are broad enough to capture the three research questions outline above. The search strategy can be found in the Appendix.

***Stage 3: Study selection***

Studies will be considered for inclusion if they assess oncological outcomes or QoL related to PA in patients who receive ICIs for their cancer, or if they assess potential underlying biological mechanisms for a link between PA and biological processes involved in immun7otherapy treatment. Hence, we will include observational studies, randomised controlled trials (RCTs), and pre-clinical studies. We understand that there will be strengths and limitations to all types of studies and these will be discussed more within the results of the scoping review. Studies will be excluded if the publication is not available in English. All papers derived from the digital search process will be uploaded to Excel using a reference management software (EndNote). From these references, we will then document the exclusion process of the studies; initially excluding irrelevant studies based on title alone, then based on abstracts. Two review authors will screen the studies independently. Any lack of consensus will be discussed with a third review author. After screening titles and abstracts, the full articles will be read and considered for the review; those excluded will have recorded evidence as to why this was necessary. For studies that have multiple publications of the same outcome(s) reported, the one with the longest follow up will be included.

***Stage 4: Charting the data***

Two independent reviewers will conduct this process. The data extraction table produced will include at least the following headings:

* Author(s)
* Year of publication
* Origin/country of origin (where the study was published or conducted)
* Aims/purpose
* Study population
* Study design
* PA type + details (e.g. lifestyle, aerobic, strength, timings, dosage)
* Supervised / unsupervised PA
* Study aims and outcomes investigated(e.g. oncological outcome, QoL, biological mechanism)
* Key findings that relate to scoping review objectives (including any assessment of feasibility of intervention)

***Stage 5: Collating, summarising and reporting the results***

As per the methodological guidelines developed by Levac *et al*, this stage will consist of three distinct steps: analysing the data, reporting results and applying meanings to the results [11] .   
For the first two research aims, where possible, we will perform a quantitative analysis and evaluate both measurements for oncological outcomes (e.g. 5-year survival rates, recurrence, response rates) and QoL (e.g. validated questionnaires). In addition, we will describe the current research in terms of evidence available (e.g. RCTs vs observational data). For the third research question, we will provide a summary of the extent to which current findings support a biological link between physical activity and immunotherapy outcomes, and if so what the content of these findings are. The studies will be compared in a narrative manner. Findings will be reported in accordance with the PRISMA-ScR extension for scoping reviews [13].

***Stage 6: Consultation***

This scoping review is a first phase in a multistage research programme aimed at developing a feasibility PA intervention for cancer patients on ICIs. To ensure that our assessment of the existing evidence for the potential role of PA in cancer ICIs, we also aim to include a consultation phase in this scoping review. The results from this scoping review combined with the consultation phase will then lead to development of a strategy for further research into this field – e.g. an RCT based on an exercise intervention for cancer patients on ICIs with a translational component to investigate underlying biological mechanisms.

This consultation phase is part of our Patient and Public Involvement (PPI) strategy as we will work actively in partnership with patients, healthcare professionals and scientists to better understand how we can design future research into PA and ICIs [14]. More specifically, we will run a focus group with patient representatives, immunologists, healthcare professionals, physiotherapists, and epidemiologists to help identify whether the results of the scoping review truly reflect the gaps in current research.

**Patient and Public Involvement**

Patients, healthcare professionals and scientists will be involved during the consultation phase (Stage 6) of the study.

**Dissemination and ethics**

As outlined above, this scoping review with a consultation phase will constitute the first stage in a multistage research programme aimed at developing a PA intervention for cancer patients on ICIs.

As the scoping review methodology is based on reviewing and collecting data from publicly available materials, this study does not require ethics approval. The consultation stage will be carried out as part of PPI, so does not require ethical approval either. To facilitate knowledge translation activities, we will liaise with relevant stakeholders through patient advocate and healthcare professional organisations.

**Author contribution**

Study concept, design and planning: CM, RR, LF, CM, GG, SK, DE, MJ, NP, BR and MVH. Protocol writing and review: CM, RR, LF, CM, GG, SK, DE, MJ, NP, BR and MVH.

**Conflicts of interest**:

No, there are no competing interests for any author

**REFERENCES**

1. Cancer Research UK. Cancer Incidence Statistics [Internet]. 2020 [cited 2020 Oct 12]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence

2. World Health Organisation. Physical Activity [Internet]. Vol. 2021. 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/physical-activity

3. Koelwyn GJ, Wennerberg E, Demaria S, et al. Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. Oncology (Williston Park) [Internet]. 2015;29(12):908–22. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26676894

4. Fox L, Cahill F, Burgess C, et al. Real World Evidence: A Quantitative and Qualitative Glance at Participant Feedback from a Free-Response Survey Investigating Experiences of a Structured Exercise Intervention for Men with Prostate Cancer. Biomed Res Int. 2017;2017:3507124–3507124.

5. Sheill G, Brady L, Guinan E, et al. The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. Trials. 2017;18(1):456–456.

6. Christensen J, Simonsen C, Hojman P. Exercise Training in Cancer Control and Treatment. Compr Physiol. 2020;9(1):165–205.

7. Idorn M, Thor Straten P. Exercise and cancer: from “healthy” to “therapeutic”? Cancer Immunol Immunother [Internet]. 2017/03/21. 2017;66(5):667–71. Available from: https://pubmed.ncbi.nlm.nih.gov/28324125

8. Wennerberg E, Lhuillier C, Rybstein MD, et al. Exercise reduces immune suppression and breast cancer progression in a preclinical model. Oncotarget [Internet]. 2020;11(4):452–61. Available from: https://pubmed.ncbi.nlm.nih.gov/32064049

9. Belcher D, Enting D, Fox L, et al. Characteristics of bladder cancer patients underoing immunotherapy - are they a suitable population for an exercise intervention programme? Second Bladder Cancer Translational Research Meeting. Birmingham: Frontiers in Oncology; 2020.

10. Joseph M, Enting D. Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. Front Oncol [Internet]. 2019;9:1270. Available from: https://pubmed.ncbi.nlm.nih.gov/31824850

11. Aromataris E, Munn Z. JBI Manual For Evidence Synthesis. 2020.

12. Levac D, Colquhoun H, O’Brien K. Scoping studies: advancing the methodology. Implement Sci. 2010;5(69).

13. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and ExplanationThe PRISMA-ScR Statement. Ann Intern Med [Internet]. 2018;169(7):467–73. Available from: https://doi.org/10.7326/M18-0850

14. Baxter S, Clowes M, Muir D, et al. Supporting public involvement in interview and other panels: a systematic review. Heal Expect [Internet]. 2016/08/19. 2017;20(5):807–17. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27535876